Bright Minds Biosciences Inc. cash flow to debt ratio of -6.91K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Bright Minds Biosciences Inc.'s free cash flow has decreased 369.77% from $-1.85M last year to $-8.69M, signaling decreasing performance

Bright Minds Biosciences Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Bright Minds Biosciences Inc.'s debt has decreased relative to shareholder equity from 0.02 last year to 0.00 today, signaling strengthened financials

Bright Minds Biosciences Inc. has a net cash position, so leverage is healthy.

Bright Minds Biosciences Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Bright Minds Biosciences Inc. has insufficient data to evaluate this check.

Bright Minds Biosciences Inc.'s short-term assets of $84.31M exceed its short-term liabilities of $2.34M

Bright Minds Biosciences Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Bright Minds Biosciences Inc.'s return on equity of -12.56%, is lower than 15.00%, indicating bad performance

Bright Minds Biosciences Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Bright Minds Biosciences Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Bright Minds Biosciences Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Bright Minds Biosciences Inc. has negative free cash flow, indicating cash burn

Bright Minds Biosciences Inc.'s yearly earnings has decreased 336.46% since last year from $-2.80M to $-12.23M, signaling decreasing performance

Bright Minds Biosciences Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -12.92% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Bright Minds Biosciences Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Bright Minds Biosciences Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Bright Minds Biosciences Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Bright Minds Biosciences Inc. is overvalued relative to its fair value price of 9.44 based on Base Cash Flow Valuation (DCF) model

Bright Minds Biosciences Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Bright Minds Biosciences Inc. is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

Bright Minds Biosciences Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Bright Minds Biosciences Inc. has insufficient data to evaluate this check.

Bright Minds Biosciences Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Bright Minds Biosciences Inc. has a price-to-book ratio of 2.08x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Bright Minds Biosciences Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue